Dr. John Cush RheumNow
1 year 8 months ago
Dazukibart Effective in Adults with Dermatomyositis
Lancet reports that the use of dazukibart, a selective monoclonal antibody against interferon B (IFNβ), was clinically effective in reducing disease activity in adults with active dermatomyositis (DM).… https://t.co/7oRyxrFpar https://t.co/wA06Kzsdqg
Dr. John Cush RheumNow
1 year 8 months ago
Just published, a new review of Axial spondyloarthritis from Baraliakos, et al in Lancet! https://t.co/0pIFM1Q2jO https://t.co/iGQ3ES7Nie
Dr. John Cush RheumNow
1 year 8 months ago
Network metanalysis of 9 RCTs, 3699 patients looked at small molecule Rx in #PsA. With ACR 50/70, PASI 75, & HAQ-DI @ wk 12-16, UPA was > ADA in PASI75 (RR 1.2); Deucravacitinib > Otezla at HAQ (RR −0.16) no OTHER SIGNIF differences observed https://t.co/WQCFQDnnft https://t.co/7NTNIpzEuG
Dr. John Cush RheumNow
1 year 8 months ago
QD Clinic - Treating Overlap with ILD
Polyarthritis, ILD, Dermatomyositis - how to treat?
Features Dr. Jack Cush.
QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6
https://t.co/CsIpdS8hyd https://t.co/I92p5U3UTp
Dr. John Cush RheumNow
1 year 8 months ago
Screening for Osteoporosis to Prevent Fractures - USPSTF Recommendations
The US Preventive Services Task Force (USPSTF) has done a systematic review on osteoporosis screening to prevent fractures and put forth its recent recommendations. These recommendations pertain to adults… https://t.co/gQ1vcpxih7 https://t.co/SQLJPALq3f
Dr. John Cush RheumNow
1 year 8 months ago
BACHELOR Trial - Baricitinib in Early Polymyalgia Rheumatica
Lancet reports a French study demonstrating the efficacy of baricitinib in patients with polymyalgia rheumatica (PMR).
Glucocorticoids are the mainstay of therapy in PMR patients and may be problematic in older… https://t.co/svLmE6OBWm https://t.co/K8sdROswxV
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com; and pays homage to colleagues who passed away in 2024.
A UK retrospective matched open cohort study shows that children who suffered frmo abuse, neglect or domestic abuse carry a significantly increased risk of developing rheumatoid arthritis or psoriasis in later life. Researchers used Dexter software and over 16 million Electronic Health Records, to define two cohorts, one arm that was exposed to childhood maltreatment, and one arm that was not.
A nationwide cohort study of patients with multisystem inflammatory syndrome in children (MIS-C), a life-threatening complication of COVID-19 infection, showed that many had severe disease during the acute phase, but most recovered quickly and had a reassuring midterm prognosis.
Dr. John Cush RheumNow
1 year 8 months ago
CDC/ACIP 2025 new Immunization recommendations w/ new vaccine recs for COVID-19, influenza, meningococcal serogroup B, pneumococcal, & RSV. Influenza vaccines have been changed from the quadrivalent to trivalent formulations. https://t.co/Kh1NXMuhVU https://t.co/CRq87PZ31j
Dr. John Cush RheumNow
1 year 8 months ago
QD Clinic - Acute Neck & Back Pain
Acute onset febrile, polyarthritis, neck and low back pain
Features Dr. Jack Cush.
QD Clinics - lessons from the clinic, sponsored by RNL2025 in Dallas, TX; Feb 8 & 9, 2025
Register at https://t.co/2dcFVgu8z6
https://t.co/2GqyqXAjbF https://t.co/vIeqdHyayV
Dr. John Cush RheumNow
1 year 8 months ago
2024 In Memorium
Sadly, in 2024, Rheumatology lost many of our greatest brethren, mentors, do-gooders and clinicians. These clinicians were responsible for the care of hundreds of thousands with MSK problems, while driving the scientific advances that will shape the lives of… https://t.co/c8xvPyXbft https://t.co/TEQihNmZnr
Dr. John Cush RheumNow
1 year 8 months ago
🚨 RheumNow Live 2025: Redefining Rheumatology 🚨
Join top experts & innovators shaping the future of rheumatology care! 💡 Cutting-edge research, interactive sessions, expert insights, & exclusive access await.
Be part of the change. Register now! 👉 https://t.co/AQbd7NC2wz… https://t.co/AcmKxGBLvb https://t.co/QlZoAhm8h8
